Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor

Molecular Endocrinology

Volumn 25, Issue 9, 2011, Pages 1527-1538

  Wang, Chunyu ^a   Mayer, Julie Ann ^a   Mazumdar, Abhijit ^a   Fertuck, Kirsten ^b,c   Kim, Heetae ^d   Brown, Myles ^b   Brown, Powel H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BOSTON COLLEGE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ESTROGEN; ESTROGEN RECEPTOR; LUCIFERASE; PROTEIN P300; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR SP1;

ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE PROGRESSION; CHROMATIN IMMUNOPRECIPITATION; ESTROGEN RESPONSIVE ELEMENT; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; ONCOGENE C MYC; PRIORITY JOURNAL;

BASE SEQUENCE; BINDING SITES; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; CREB-BINDING PROTEIN; E1A-ASSOCIATED P300 PROTEIN; ENHANCER ELEMENTS, GENETIC; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUCIFERASES; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, ESTROGEN; RESPONSE ELEMENTS; RNA, SMALL INTERFERING; SEQUENCE DELETION; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP-1;

MAMMALIA;

EID: 80052290466     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2011-1037     Document Type: Article

References (48)

1. Jemal A, Siegel R, Xu J, Ward E 2010 Cancer statistics, 2010. CA Cancer J Clin 60:277-300.
2. Carroll JS, Brown M 2006 Estrogen receptor target gene: an evolving concept. Mol Endocrinol 20:1707-1714.
3. Hall JM, Couse JF, Korach KS 2001 The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 276: 36869-36872.
4. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Ström A, Treuter E, Warner M, Gustafsson JA. 2007 Estrogen receptors: how do they signal and what are their targets. Physiol Rev 87:905-931.
5. Klinge CM 2001 Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 29:2905-2919.
6. Kushner PJ, Agard D, Feng WJ, Lopez G, Schiau A, Uht R, Webb P, Greene G 2000 Oestrogen receptor function at classical and alternative response elements. Novartis Found Symp 230:20-26; discussion 27-40.
7. Safe S, Kim K 2008 Non-classical genomic estrogen receptor (ER)/ specificity protein and ER/activating protein-1 signaling pathways. J Mol Endocrinol 41:263-275.
8. Kalaitzidis D, GilmoreTD2005 Transcription factor cross-talk: the estrogen receptor and NF-kB. Trends Endocrinol Metab 16:46-52.
9. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S, Sementchenko V, Fox EA, Silver PA, Gingeras TR, Liu XS, BrownM2006 Genome-wide analysis of estrogen receptor binding sites. Nat Genet 38:1289-1297.
10. Lin CY, Vega VB, Thomsen JS, Zhang T, Kong SL, Xie M, Chiu KP, Lipovich L, Barnett DH, Stossi F, Yeo A, George J, Kuznetsov VA, Lee YK, Charn TH, Palanisamy N, Miller LD, Cheung E, Katzenellenbogen BS, Ruan Y, Bourque G, Wei CL, Liu ET 2007 Whole-genome cartography of estrogen receptor α binding sites. PLoS Genet 3:e87.
11. DeNardo DG, Kim HT, Hilsenbeck S, Cuba V, Tsimelzon A, Brown PH 2005 Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/activator protein-1-dependent genes. Mol Endocrinol 19:362-378.
12. Brown PH, Alani R, Preis LH, Szabo E, Birrer MJ 1993 Suppression of oncogene-induced transformation by a deletion mutant of c-jun. Oncogene 8:877-886.
13. Brown PH, Chen TK, Birrer MJ 1994 Mechanism of action of a dominant-negative mutant of c-Jun. Oncogene 9:791-799.
14. Ludes-Meyers JH, Liu Y, Muñoz-Medellin D, Hilsenbeck SG, Brown PH. 2001 AP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene 20:2771-2780.
15. Zeller KI, Zhao X, Lee CW, Chiu KP, Yao F, Yustein JT, Ooi HS, Orlov YL, Shahab A, Yong HC, Fu Y, Weng Z, Kuznetsov VA, Sung WK, Ruan Y, Dang CV, Wei CL 2006 Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci USA 103:17834-17839.
16. Meyer N, Penn LZ 2008 Reflecting on 25 years with MYC. Nat Rev Cancer 8:976-990.
17. Nass SJ, Dickson RB 1997 Defining a role for c-Myc in breast tumorigenesis. Breast Cancer Res Treat 44:1-22.
18. Pelengaris S, Khan M, Evan G 2002 c-MYC: more than just a matter of life and death. Nat Rev Cancer 2:764-776.
19. Liao DJ, Dickson RB 2000 c-Myc in breast cancer. Endocr Relat Cancer 7:143-164.
20. Biéche I, Laurendeau I, Tozlu S, Olivi M, Vidaud D, Lidereau R, Vidaud M. 1999 Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res 59:2759-2765.
21. Wang YH, Liu S, Zhang G, Zhou CQ, Zhu HX, Zhou XB, Quan LP, Bai JF, Xu NZ 2005 Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res 7:R220-R228.
22. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M 2000 Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103:843-852.
23. Shang Y, Brown M 2002 Molecular determinants for the tissue specificity of SERMs. Science 295:2465-2468.
24. Cheng AS, Jin VX, Fan M, Smith LT, Liyanarachchi S, Yan PS, Leu YW, Chan MW, Plass C, Nephew KP, Davuluri RV, Huang TH 2006 Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-α responsive promoters. Mol Cell 21:393-404.
25. Wierstra I, Alves J 2008 The c-myc promoter: still MysterY and challenge. Adv Cancer Res 99:113-333.
26. Miller TL, Huzel NJ, Davie JR, Murphy LC 1993 C-myc gene chromatin of estrogen receptor positive and negative breast cancer cells. Mol Cell Endocrinol 91:83-89.
27. Dubik D, Dembinski TC, Shiu RP 1987 Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res 47:6517-6521.
28. Dubik D, Shiu RP 1992 Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 7:1587-1594.
29. Dubik D, Shiu RP 1988 Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells. J Biol Chem 263:12705-12708.
30. Davidson NE, Prestigiacomo LJ, Hahm HA 1993 Induction of jun gene family members by transforming growth factor α but not 17β-estradiol in human breast cancer cells. Cancer Res 53:291-297.
31. Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, Brown PH 2002 Inhibition of AP-1 transcription factor causes blockade of multiplesignal transduction pathways and inhibits breast cancer growth. Oncogene 21:7680-7689.
32. Liu Y, Lu C, Shen Q, Munoz-Medellin D, Kim H, Brown PH 2004 AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity. Oncogene 23:8238-8246.
33. Miller TL, Jin Y, Sun JM, Coutts AS, Murphy LC, Davie JR 1996 Analysis of human breast cancer nuclear proteins binding to the promoter elements of the c-myc gene. J Cell Biochem 60:560-571.
34. DesJardins E, Hay N 1993 Repeated CT elements bound by zinc finger proteins control the absolute and relative activities of the two principal human c-myc promoters. Mol Cell Biol 13:5710-5724.
35. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P 2000 Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 74:311-317.
36. Webb P, Nguyen P, Valentine C, Lopez GN, Kwok GR, McInerney E, Katzenellenbogen BS, Enmark E, Gustafsson JA, Nilsson S, Kushner PJ 1999 The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol 13:1672-1685.
37. Cicatiello L, Addeo R, Sasso A, Altucci L, Petrizzi VB, Borgo R, Cancemi M, Caporali S, Caristi S, Scafoglio C, Teti D, Bresciani F, Perillo B, Weisz A 2004 Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. Mol Cell Biol 24:7260-7274.
38. Barkhem T, Haldosén LA, Gustafsson JA, Nilsson S 2002 pS2 Gene expression in HepG2 cells: complex regulation through crosstalk between the estrogen receptor α, an estrogen-responsive element, and the activator protein 1 response element. Mol Pharmacol 61: 1273-1283.
39. De Bosscher K, Vanden Berghe W, Haegeman G 2006 Cross-talk between nuclear receptors and nuclear factor kB. Oncogene 25: 6868-6886.
40. Pfahl M 1993 Nuclear receptor/AP-1 interaction. Endocr Rev 14: 651-658.
41. Herrlich P 2001 Cross-talk between glucocorticoid receptor and AP-1. Oncogene 20:2465-2475.
42. Karin M, Chang L 2001 AP-1-glucocorticoid receptor crosstalk taken to a higher level. J Endocrinol 169:447-451.
43. Mehta K 2003 Retinoids as regulators of gene transcription. J Biol Regul Homeost Agents 17:1-12.
44. Uray IP, Shen Q, Seo HS, Kim H, Lamph WW, Bissonnette RP, Brown PH 2009 Rexinoid-induced expression of IGFBP-6 requires RARβ-dependent permissive cooperation of retinoid receptors and AP-1. J Biol Chem 284:345-353.
45. Lopez G, Schaufele F, Webb P, Holloway JM, Baxter JD, Kushner PJ 1993 Positive and negative modulation of Jun action by thyroid hormone receptor at a unique AP1 site. Mol Cell Biol 13:3042-3049.
46. Dai D, Litman ES, Schonteich E, Leslie KK 2003 Progesterone regulation of activating protein-1 transcriptional activity: a possible mechanism of progesterone inhibition of endometrial cancer cell growth. J Steroid Biochem Mol Biol 87:123-131.
47. Jiang C, Ito M, Piening V, Bruck K, Roeder RG, Xiao H 2004 TIP30 interacts with an estrogen receptor α-interacting coactivator CIA and regulates c-myc transcription. J Biol Chem 279:27781-27789.
48. Strecker TE, Shen Q, Zhang Y, Hill JL, Li Y, Wang C, Kim HT, Gilmer TM, Sexton KR, Hilsenbeck SG, Osborne CK, Brown PH 2009 Effect of lapatinib on the development of estrogen receptornegative mammary tumors in mice. J Natl Cancer Inst 101:107-113.